HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.

Abstract
Burkholderia mallei and B. pseudomallei are important human pathogens and cause the diseases glanders and melioidosis, respectively. Both organisms are highly infectious when inhaled and are inherently resistant to many antimicrobials, thus making it difficult to treat pneumonic Burkholderia infections. We investigated whether it was possible to achieve rapid protection against inhaled Burkholderia infection by using inhaled immunotherapy. For this purpose, cationic liposome DNA complexes (CLDC), which are potent activators of innate immunity, were used to elicit the activation of pulmonary innate immune responses. We found that mucosal CLDC administration before or shortly after bacterial challenge could generate complete or nearly complete protection from inhalational challenge with 100% lethal doses of B. mallei and B. pseudomallei. Protection was found to be dependent on the CLDC-mediated induction of gamma interferon responses in lung tissues and was partially dependent on the activation of NK cells. However, CLDC-mediated protection was not dependent on the induction of inducible nitric oxide synthase, as assessed by depletion studies. We concluded that the potent local activation of innate immune responses in the lung could be used to elicit rapid and nonspecific protection from aerosol exposure to both B. mallei and B. pseudomallei.
AuthorsAndrew Goodyear, Lisa Kellihan, Helle Bielefeldt-Ohmann, Ryan Troyer, Katie Propst, Steven Dow
JournalInfection and immunity (Infect Immun) Vol. 77 Issue 4 Pg. 1579-88 (Apr 2009) ISSN: 1098-5522 [Electronic] United States
PMID19179415 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Cations
  • DNA, Bacterial
  • Liposomes
  • Interferon-gamma
Topics
  • Administration, Inhalation
  • Animals
  • Burkholderia Infections (immunology, microbiology, prevention & control, therapy)
  • Burkholderia mallei (pathogenicity)
  • Burkholderia pseudomallei (pathogenicity)
  • Cations
  • Cell Line
  • DNA, Bacterial (administration & dosage, genetics, immunology)
  • Escherichia coli (genetics)
  • Glanders (immunology, microbiology, prevention & control, therapy)
  • Humans
  • Immunotherapy (methods)
  • Interferon-gamma (biosynthesis)
  • Liposomes (administration & dosage, immunology)
  • Lung Diseases (immunology, microbiology, prevention & control, therapy)
  • Macrophages, Alveolar (microbiology)
  • Melioidosis (immunology, microbiology, prevention & control, therapy)
  • Mice
  • Mice, Inbred BALB C
  • Plasmids (administration & dosage, genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: